Colorectal Cancer

Data presented at the ESMO Congress 2022 highlighted advances across treatment modalities, including landmark data for trials in melanoma, breast cancer, and lung cancer, as well as early data that made headlines in a subgroup of patients with colon cancer.

Afsaneh Barzi, MD, PhD, discusses the need for more sensitive minimal residual disease testing in colorectal cancer.

Sam Klempner, MD, discusses the design and eligibility criteria of the ongoing phase 1/2 KRYSTAL-1 trial in colorectal cancer.

Prognosis, treatment outcomes, and molecular characteristics have become associated with sidedness in colorectal cancers making the distinction an essential characteristic for consideration in decison-making.

Benjamin Adam Weinberg, MD, discussed the expanding role of circulating tumor DNA in CRC and the various testing methods, the utilization of liquid biopsies, and the need for up-front genetic testing to identify molecular alterations.

Additional analyses of the phase 2 MOUNTAINEER trial further support the early administration of tucatinib in combination with trastuzumab as an optimal treatment strategy for patients with previously treated HER2-positive metastatic colorectal cancer.

Stacey A. Cohen, MD, discusses the evaluation of the role of circulating tumor DNA to determine the benefit of chemotherapy in colorectal cancer.

Stacey A. Cohen, MD, discusses the results of real-world analysis of patients with resected stage I-III colorectal cancer, how circulating tumor DNA status correlated with recurrence rates, and how these real-world data compared with previous observational studies.

Lutetium-177-FAP-2286 produced preliminary evidence of antitumor activity with a manageable safety profile in patients with advanced or metastatic solid tumors, according to data from the phase 1/2 LuMIERE trial.

John H. Strickler, MD, discusses the benefit of combining tucatinib with trastuzumab in HER2-positive metastatic colorectal cancer.

Celyad Oncology has discontinued development its investigational CAR T-cell therapy CYAD-101 for the treatment of patients with unresectable metastatic colorectal cancer.

Nageshwara Arvind Dasari, MD, discusses the patient population observed in the phase 3 FRESCO-2 trial in metastatic colorectal cancer.

John H. Strickler, MD, discusses the importance of investigating targeted therapies in HER2-positive metastatic colorectal cancer.

Dr Hubbard reviews patient reported outcomes from the MOUNTAINEER trial, which evaluated the combination of tucatinib plus trastuzumab in patients with HER2-positive metastatic colorectal cancer.

The addition of SCO-101 to FOLFIRI chemotherapy was safe and tolerable but failed to elicit a greater than 30% reduction in tumor volume in patients with metastatic colorectal cancer, though study of the combination will continue.

Nageshwara Arvind Dasari, MD, discusses the results of the phase 3 FRESCO-2 trial of fruquintinib in patients with refractory metastatic colorectal cancer, the significance of the data for the treatment paradigm, and the potential next steps for examining the agent in this disease.

Dr. Tanios Bekaii-Saab discusses the results of a systematic review/meta-analysis intended to assess the impact of EGFR-targeted therapies on clinical outcomes in patients with HER2-positive metastatic colorectal cancer.

The FDA has granted a priority review to a supplemental new drug application seeking the approval of tucatinib for use in combination with trastuzumab in adult patients with HER2-positive colorectal cancer who have received at least 1 prior treatment regimen for unresectable or metastatic disease.

Dose optimization of regorafenib led to improved survival outcomes compared with best supportive care of fruquintinib, standard-dose regorafenib, and trifluridine/tipiracil in patients with relapsed/refractory metastatic colorectal cancer.

The addition of bevacizumab to trifluridine/tipiracil resulted in a statistically significant improvement in overall survival over trifluridine/tipiracil alone in patients with refractory metastatic colorectal cancer after 2 chemotherapy regimens.

Adagrasib monotherapy and in combination with cetuximab generated encouraging responses in patients with advanced colorectal cancer harboring KRAS G12C mutations.

Tucatinib plus trastuzumab improved radiographic response rates in patients with metastatic HER2-positive colorectal cancer initially treated with tucatinib monotherapy who later crossed over to receive doublet therapy.

Four weeks of treatment with nivolumab plus ipilimumab elicited major pathologic responses in 95% of patients with mismatch repair–deficient colon cancer.

Research published in 2022 has advanced our understanding of the effect of neoadjuvant therapy on organ preservation for patients with locally advanced rectal cancer.

Chemotherapy prior to transanal excision surgery demonstrated favorable responses that led to increased organ preservation rates among patients with early rectal cancer, according to findings from the phase 2 NEO trial.